高氧液联合化疗治疗恶性肿瘤患者临床观察.docVIP

高氧液联合化疗治疗恶性肿瘤患者临床观察 　　[摘要] 目的：对44例恶性肿瘤患者给予高氧液联合化疗，并与只接受化疗的对照组患者进行对比分析。方法：44例恶性肿瘤患者设为治疗组，给予一线标准方案化疗，同时给予高氧液静脉输入伴随化疗每日1次。对照组患者单独采用一线标准方案化疗。2周期后观察疗效、毒副反应、KPS改善情况以及中位生存期。结果：治疗组和对照组有效率分别为23.1%和18.2%，两组比较，差异无统计学意义（P0.05）；两组中位生存期（MST）分别为31.3个月和29.8个月，两组比较，差异无统计学意义（P0.05）；治疗组和对照组的KPS改善率分别为59.6%和36.8%，两组比较，差异有统计学意义（P 　　[关键词] 恶性肿瘤；高氧液；化疗 　　[中图分类号] R730.5[文献标识码]B[文章编号]1673-7210（2011）04（a）-178-02 　　 　　Clinical analysis of hyperoxic solution combined with chemotherapy in the treatment of m alignant tumor patients 　　YANG Yaokun, ZHANG Yuechen, WANG Jianming 　　Department of Medical Oncology, the Second People′s Hospital of Fuxin City, Fuxin 123000, China 　　[Abstract] Objective: To assess the efficacy and toxicity of the combination of hyperoxic solution and chemotherapy on m alignant tumour. Methods: 44 m alignant tumor patients were enrolled into the study. They accepted the treatment of the first standard chemotherapy and hyperoxic solution. The treatment of chemotherapy and hyperoxic solution was repeated every 21-28 days. After two cycles of chemotherapy, the efficacy and toxicity were evaluated. The other 44 patients of the comparative group were only accepted the first standard chemotherapy. Results: The efficacious rates of the two groups were 23.1% (cured group) and 18.2% (comparative group), there was no significant difference (P0.05). The median survival time(MST) of the two groups were 31.3 months and 29.8 months, there was no significant difference (P0.05). The KPS improvement of the two groups were 59.6% and 36.8%, there was a significant difference (P0.05；χ2=0.0810.05）。中位生存期为31.3个月，对照组为29.8个月，两组比较，差异无统计学意义（t=0.0230.05）。治疗组KPS改善率为59.6%，对照组为36.8%，两组比较，差异有统计学意义（χ2=5.95χ20.05，P 本文为全文原貌 未安装PDF浏览器用户请先下载安装 原版全文 　　 　　表1 治疗组与对照组疗效比较（例） 　　 　　2.2 毒性反应 　　化疗副反应主要为骨髓抑制、消化道反应、肝功能损害、外周神经肌肉刺激症状，两组基本相同，两组患者均无严重毒性反应发生。 　　3 讨论 　　从200多年以前Priestley发现氧气后，氧疗逐渐在医学界广泛应用。给氧方式包括经鼻给氧、高压氧仓、机械通气给氧和静脉输氧等。近年来国内正逐步开展的静脉输氧是对呼吸道不能充分给氧的一种补充，可直接迅速提高局部病灶氧分压，改善微氧环境，对增强肿瘤乏氧细胞的放化疗